Learn · Compounded GLP-1s
Compounded tirzepatide vs Zepbound
Same molecule, different product. Who makes each one, what has and has not been tested, how the prices actually compare once membership fees are counted, why the devices differ, and what the law allows in 2026.
Last updated September 16, 2026
Zepbound is Eli Lilly's FDA-approved tirzepatide, made in FDA-inspected factories and sold in fixed-dose pens and vials. Compounded tirzepatide contains the same active molecule but is mixed by a pharmacy from bulk ingredient, usually into a multi-dose vial you measure yourself, and is not FDA-approved — the agency does not review it for safety, effectiveness or quality. Every published trial result for tirzepatide belongs to the Lilly product. The compounded version is cheaper at starting doses, but once membership fees and maintenance pricing are counted the gap is often small, and at the top doses it can disappear.
Key takeaways
- Same active molecule, different finished product. "Same active ingredient" is a statement about chemistry, not about manufacturing, testing or oversight.
- Zepbound's trial results do not transfer. The 20.9% mean weight reduction at 15 mg was measured on Lilly's product; no compounded tirzepatide has been through a trial.
- Zepbound self-pay from LillyDirect is $299 (2.5 mg), $399 (5 mg) and $449 (7.5–15 mg when refilled within 45 days). Compounded tirzepatide is advertised at $90–$216 at starting doses and $279–$349 ongoing, usually plus a $39–$149 membership.
- The devices differ, and that is a safety difference: a fixed-dose pen versus a vial and a syringe, where the FDA has documented overdoses of five to 20 times the intended dose.
- Since the tirzepatide shortage ended, a compounded version is lawful only as a patient-specific preparation a prescriber documents as meaningfully different — which is why providers call theirs "personalized".
First, the names
Most of the confusion in this comparison is vocabulary, and it is worth clearing before anything else.
Tirzepatide is the molecule. It activates two gut-hormone receptors, GLP-1 and GIP.
Zepbound is Eli Lilly's brand of tirzepatide approved for weight management, and for obstructive sleep apnea in adults with obesity. Mounjaro is the same molecule from the same company, approved for type 2 diabetes. Both come from Lilly's factories and both have been reviewed by the FDA.
Compounded tirzepatide is a pharmacy-made preparation containing the tirzepatide active ingredient. It is not a brand, not a generic and not an approved product. So "tirzepatide vs compounded tirzepatide" and "compounded vs non-compounded tirzepatide" are the same question as this page's title, and "compounded tirzepatide vs Mounjaro" differs only in which approved brand you compare against.
There is no generic tirzepatide in the United States. Tirzepatide is still under patent, so a compounded product is not an early generic — it is made under a different part of the law, which does not require FDA approval or proof of equivalence.
The differences, side by side
Everything below is checkable. It is the difference between two products, not between a good one and a bad one.
| Zepbound (and Mounjaro) | Compounded tirzepatide | |
|---|---|---|
| Made by | Eli Lilly, in FDA-inspected facilities | A 503A pharmacy or 503B outsourcing facility |
| FDA approval | Approved; reviewed for safety, effectiveness and quality | Not approved; not reviewed before sale |
| Clinical trials of this product | Yes — 72-week trials in thousands of patients | None |
| Form | Single-dose pen or vial at fixed strengths; multi-dose KwikPen | Usually a multi-dose vial you draw from with a syringe; sometimes tablets or drops |
| Dose | Set by the label: 2.5, 5, 7.5, 10, 12.5, 15 mg | Set by the prescriber; concentrations vary by pharmacy and can change between vials |
| Other ingredients | Only the approved formulation | Sometimes vitamin B12, glycine or niacinamide, often to make the product "different" from the brand |
| Self-pay price, Sept 2026 | $299 / $399 / $449 a month by dose, from LillyDirect | $90–$216 headline, $279–$349 ongoing, plus any membership |
| Who is accountable | Eli Lilly, under federal drug law | The pharmacy (state board), the prescriber, and the telehealth company's policies |
| Adverse events reported to FDA | Required | Required of 503B facilities; not of state-licensed pharmacies |
Is it the same drug?
The active ingredient is the same molecule. Everything downstream of that sentence is where products differ, and it is the part marketing tends to compress into "same active ingredient as Zepbound" — a phrase the FDA has cited in warning letters precisely because of what it implies.
What is not established by sameness of the molecule: the concentration in your vial, the purity of the bulk ingredient, whether anything else was added, whether the sterile filling was done to manufacturing standards, how stable it is over the weeks you will keep it, and whether the dose that reaches you matches the dose that was intended.
None of those is a hypothetical concern invented for this page. Each is something the FDA has written about in the compounded-GLP-1 context: unapproved salt forms, ingredients from unlisted suppliers, added B12 used to claim difference from the brand, and dosing errors from multi-dose vials.
The reverse overstatement is also wrong. A compounded product from a reputable pharmacy, at a correct concentration, measured correctly, is the same molecule doing the same thing in your body. The honest position is that you cannot verify any of those conditions yourself, and with the approved product you do not have to.
Does compounded tirzepatide work as well?
Nobody can answer that with evidence, and the absence is the answer worth having.
The numbers everyone quotes for tirzepatide come from Zepbound's registration trials: over 72 weeks, a mean weight reduction of 20.9% at 15 mg, 19.5% at 10 mg and 15.0% at 5 mg, against 3.1% on placebo, with a reduced-calorie diet and increased activity in every arm. Those results belong to a specific manufactured formulation in a specific device.
No compounded tirzepatide product has been through a trial. It is reasonable to expect the same molecule at the same delivered dose to behave similarly, and many people report that it does. It is not reasonable to present Zepbound's percentages as a compounded product's expected result, and a provider that does so is describing a study it did not run on a product it does not make.
What can be said: if the concentration is right, the measurement is right, and the product is what it says it is, you are taking tirzepatide. Those three conditions are the whole question.
The price comparison, done properly
This is the reason most people are on this page, and the headline numbers mislead in both directions. The honest comparison uses the all-in monthly cost at the dose you will actually be taking, not the introductory price at the starting dose.
- The advertised price is almost always the lowest dose. Providers quote 2.5 mg or a "microdose" tier; most people end up higher.
- Membership is the hidden half. A $279 medication price with a $99 membership is $378 a month, which is not far from Zepbound's $399 at 5 mg.
- Prepaid plans cut the price and raise the commitment. Several providers require the balance of a multi-month plan to be paid out if you cancel.
- Lilly's price depends on refilling within 45 days. Miss it at the higher doses and $449 becomes $699.
- Our live, dated tables do this arithmetic for every provider we track: cheapest compounded tirzepatide and tirzepatide cost without insurance, with Zepbound's own page alongside.
| Zepbound from LillyDirect | Compounded tirzepatide from a telehealth provider | |
|---|---|---|
| Starting dose | $299 (2.5 mg) | $90–$216 advertised, often on a prepaid term |
| Mid dose | $399 (5 mg) | Rises with dose at most providers |
| Maintenance | $449 (7.5–15 mg, refilled within 45 days) | $279–$349 where published |
| Membership fee | None | $39–$149 a month at most providers, billed separately |
| All-in at maintenance | $449 | roughly $318–$498 |
| If you miss the 45-day refill window | $499 (7.5 mg) or $699 (10–15 mg) | Not applicable |
The device difference is a safety difference
Zepbound comes as a single-dose pen or vial at a fixed strength, or a KwikPen holding four weekly doses. You do not calculate anything: the dose is the device.
A compounded product usually arrives as a multi-dose vial at a concentration the pharmacy chose — 10 mg/mL and 17 mg/mL are common — and you draw each dose with an insulin syringe, measured in "units". Three units of measurement are in play at once: milligrams, millilitres and syringe units.
This is where the FDA's documented harm in this category comes from. The agency has described patients administering five to 20 times the intended dose after confusing units — someone told to draw 5 units drawing 50, a prescriber writing "25 units" when 0.25 mg meant 5 units. Reported effects included severe vomiting, dehydration, fainting, acute pancreatitis and gallstones, some requiring hospital care.
If you use a compounded product, get the dose written in the same units marked on your syringe, and re-check the concentration printed on every new vial. Is compounded tirzepatide safe? covers the rest.
What the law allows in 2026
Compounded tirzepatide became a mass-market product during a shortage. The FDA declared that shortage resolved on 2 October 2024, enforcement discretion ended in February and March 2025, and the Fifth Circuit upheld the FDA's decision on 27 August 2026.
What remains is a narrow exception: a compounder may make what would otherwise be a copy of an approved drug where a prescriber determines that a change, made for an identified individual patient, will produce a significant difference for that patient. That is the basis for every "personalized" tirzepatide sold online — non-standard doses, added ingredients, oral or sublingual forms.
The full timeline, the 503B bulks-list proposal and the enforcement record are on compounded GLP-1s explained.
Practical reading: a provider selling compounded tirzepatide should be able to name the pharmacy that makes it and explain why your prescription is patient-specific — and should never tell you it is "the same as Zepbound".
How to decide between them
Both are real options and the choice is genuinely personal. These are the questions that decide it:
- Does insurance cover Zepbound for you? If so, the comparison usually ends there — a covered copay beats both cash prices.
- What will you pay all-in at your maintenance dose? Not the advertised starting price. Medication plus membership, after the introductory period.
- How comfortable are you measuring a dose from a vial? If the answer is "not very", the fixed-dose pen is worth real money.
- Do you want a product that has been tested as sold? Only one of these two has.
- Who is the pharmacy, and what form of the ingredient does it use? A provider that will not answer is answering.
- What happens if you want to stop? Prepaid compounded plans often have to be paid out; LillyDirect is bought fill by fill.
Frequently asked
Is compounded tirzepatide the same as Zepbound?
It contains the same active molecule, but it is not the same product. Zepbound is made by Eli Lilly, is FDA-approved, has been through 72-week clinical trials and comes in fixed-dose pens and vials. Compounded tirzepatide is mixed by a pharmacy, is not FDA-approved, has never been trialled as sold, and usually comes in a multi-dose vial at a concentration the pharmacy chose. The FDA has sent warning letters to telehealth companies for describing compounded products as the same as approved drugs.
Does compounded tirzepatide work as well as Zepbound?
Nobody knows, because it has never been tested. The published results — a 20.9% mean weight reduction at 15 mg over 72 weeks — were measured on Lilly's product. The same molecule at the same delivered dose would be expected to behave similarly, but that depends on the concentration being right, the ingredient being what it claims and the dose being measured correctly, none of which you can verify yourself.
Is compounded tirzepatide cheaper than Zepbound?
At starting doses, usually yes: $90 to $216 a month advertised against $299 for Zepbound's 2.5 mg vial. At maintenance doses it is much closer. Compounded ongoing prices run $279 to $349 where published, plus a membership of $39 to $149, which lands at roughly $318 to $498 all-in against Zepbound's $449 at 7.5–15 mg when refilled within 45 days.
What is the difference between compounded tirzepatide and Mounjaro?
The same difference as with Zepbound, since Mounjaro is the same molecule from the same manufacturer. Mounjaro is Lilly's tirzepatide approved for type 2 diabetes rather than weight management, sold at $499 a month self-pay at every dose. A compounded product is a pharmacy-made preparation that is not approved for any indication.
Can I switch from compounded tirzepatide to Zepbound?
That is a prescriber's decision, and there is no published conversion between them — a compounded dose depends on the concentration of your vial, while Zepbound's doses are fixed by its label. In practice a prescriber will place you on a labelled Zepbound dose and follow the label's escalation steps. Ask before assuming your current milligram figure maps onto a Zepbound strength.
Is compounded tirzepatide legal in 2026?
Only as a patient-specific prescription. The tirzepatide shortage was declared resolved in October 2024, enforcement discretion for compounders ended in February and March 2025, and the Fifth Circuit affirmed the FDA's position on 27 August 2026. A compounder may still make a version that a prescriber documents as meaningfully different for an individual patient, which is how telehealth providers continue to sell it.
Rate GLP-1 editorial team
Researches provider pricing, licensing and public ratings from primary sources and re-verifies every profile on a published schedule.
September 16, 2026
Educational information, not medical advice. Checked against the sources below; regulations and prices change often. Medical disclaimer
Sources
- Zepbound (tirzepatide) prescribing information, revised 08/2026 — §1 indications, §2 dosage, §14.1 weight-reduction trials — accessed September 16, 2026
- Mounjaro (tirzepatide) prescribing information, revised 08/2026 — §1 indications — accessed September 16, 2026
- LillyDirect: Zepbound self-pay pricing — accessed September 12, 2026
- FDA: Compounding and the FDA — questions and answers — accessed September 16, 2026
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss — accessed September 16, 2026
- FDA alert: dosing errors associated with compounded injectable semaglutide (2024-07-26) — accessed September 16, 2026
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — accessed September 16, 2026
- Fifth Circuit opinion No. 25-10758 affirming the FDA shortage decision (2026-08-27) — accessed September 12, 2026